While policy debates continue over the 15-year horizon for the National Health Insurance (NHI) and its planned Single Electronic Health Record (SEHR), a quieter, faster transformation has already ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...

Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs. The agreement ...

Bristol-Myers Squibb (BMS) reported stronger-than-expected earnings for the fourth quarter of 2025, with earnings per share (EPS) reaching $1.26, surpassing the anticipated $1.12. Revenue also ...

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Bristol Myers Squibb is leaning heavily on its newer key products, grouped into its growth portfolio category, to weather the storm it expects as it heads toward further declines within its legacy ...

Cardi B and Stefon Diggs broke up last month.

From today, thousands more Australians living with advanced and rare cancers will have access to affordable immunotherapy treatment options through ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor ...

Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor Relations website at http ...